What is the target price for Regeneron Pharmaceuticals (regn) stock?
18 brokers have issued 1 year target prices for Regeneron Pharmaceuticals' shares. Their predictions range from $320.00 to $480.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $385.38 in the next year.
Does REGON Pharmaceuticals stock pay a dividend?
Regeneron Pharmaceuticals does not currently pay a dividend. Regeneron Pharmaceuticals does not have a long track record of dividend growth. In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought.
Where can I buy regn shares?
Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
See more
Will Regeneron stock go back up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals Inc have a median target of 684.00, with a high estimate of 790.00 and a low estimate of 536.00. The median estimate represents a +14.93% increase from the last price of 595.12.
Is Regeneron stock a buy or sell?
Regeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.53, and is based on 12 buy ratings, 5 hold ratings, and 2 sell ratings.
Why is Regeneron going down?
In 2022's first quarter, Regeneron's sales were down 40% compared to 2021's fourth quarter. The gaping hole in the company's financials was due to REGEN-COV, its COVID-19 treatment, which didn't generate any revenue in the U.S. in Q1.
Does Regeneron stock pay dividends?
Does Regeneron pay a cash dividend? No, we have never paid a cash dividend nor do we expect to pay any dividends in the foreseeable future.
Should I invest in REGN?
Out of 15 analysts, 5 (33.33%) are recommending REGN as a Strong Buy, 5 (33.33%) are recommending REGN as a Buy, 3 (20%) are recommending REGN as a Hold, 2 (13.33%) are recommending REGN as a Sell, and 0 (0%) are recommending REGN as a Strong Sell.
Is REGN a buy today?
Today REGN ranks #1558 as buy candidate.
Who makes Regeneron stock?
Top 10 Owners of Regeneron Pharmaceuticals IncStockholderStakeShares ownedWellington Management Co. LLP2.68%2,890,203Loomis, Sayles & Co. LP2.36%2,548,047Dodge & Cox2.07%2,237,063Geode Capital Management LLC1.94%2,092,7716 more rows
Does Vertex pay a dividend?
Vertex Pharmaceuticals (NASDAQ: VRTX) does not pay a dividend.
Should I buy or sell Regeneron Pharmaceuticals stock right now?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently...
What is Regeneron Pharmaceuticals' stock price forecast for 2022?
19 analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $536.00 to $844.00. On average, they...
How has Regeneron Pharmaceuticals' stock price performed in 2022?
Regeneron Pharmaceuticals' stock was trading at $631.52 on January 1st, 2022. Since then, REGN shares have decreased by 9.5% and is now trading at...
When is Regeneron Pharmaceuticals' next earnings date?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecas...
How were Regeneron Pharmaceuticals' earnings last quarter?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Wednesday, May, 4th. The biopharmaceutical company reported $11.49...
Who are Regeneron Pharmaceuticals' key executives?
Regeneron Pharmaceuticals' management team includes the following people: Dr. Leonard S. Schleifer M.D. , Ph.D., Founder, Pres, CEO & Director (...
What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?
423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com . Leonard S. Schleifer has an approval rating of 87%...
Who are some of Regeneron Pharmaceuticals' key competitors?
Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Bi...
What other stocks do shareholders of Regeneron Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NV...
When will Regeneron release its earnings?
What is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Regeneron Pharmaceuticals.
How much does Regeneron make?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
What is the NASDAQ symbol for Regeneron?
Regeneron Pharmaceuticals has a market capitalization of $62.47 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $28.66 on an earnings per share basis.
When is Regeneron earnings call?
Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
Does Regeneron pay dividends?
Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
What is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals does not currently pay a dividend.
Is Regeneron a monoclonal antibody?
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products including: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthri
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
tis. Regeneron is also developing monoclonal antibodies with Sanofi in immun ology and cancer , and bispecific antibodies and antibody cocktails with other collaborators and independently.
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
